AML3D Limited (ASX:AL3)

Market Cap	150.13M
Revenue (ttm)	10.44M
Net Income (ttm)	-4.05M
Shares Out	545.94M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,564,801
Average Volume	4,182,434
Open	0.2750
Previous Close	0.2800
Day's Range	0.2600 - 0.2800
52-Week Range	0.1050 - 0.3400
Beta	0.73
RSI	55.71
Earnings Date	Aug 22, 2025

About Ligand Pharmaceuticals

AML3D Limited provides 3D printing systems and contract manufacturing services to the aerospace, marine, defence, oil and gas, mining, and general manufacturing sectors in Australia, Singapore, and the United States. The company produces metal components and structures through automated wire-fed 3D printing technology. It designs and constructs ARCEMY 3D printing modules for sale or lease; and 3D parts using wire-arc additive manufacturing technology; as well as provides licensing, service, and technical support for customers. AML3D Limited was...

• Industry: Metal Fabrication
• Sector: Industrials
• Founded: 2014
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: AL3

Financial Performance

In 2024, AML3D's revenue was 7.32 million, an increase of 1054.57% compared to the previous year's 634,422. Losses were -4.17 million, -23.30% less than in 2023.